Aurinia Pharmaceuticals (AUPH) Competitors $7.32 +0.11 (+1.53%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends AUPH vs. IGMS, YMAB, RCKT, CYRX, AMRN, CYBN, TGTX, PBH, MRUS, and PRGOShould you be buying Aurinia Pharmaceuticals stock or one of its competitors? The main competitors of Aurinia Pharmaceuticals include IGM Biosciences (IGMS), Y-mAbs Therapeutics (YMAB), Rocket Pharmaceuticals (RCKT), Cryoport (CYRX), Amarin (AMRN), Cybin (CYBN), TG Therapeutics (TGTX), Prestige Consumer Healthcare (PBH), Merus (MRUS), and Perrigo (PRGO). These companies are all part of the "pharmaceutical preparations" industry. Aurinia Pharmaceuticals vs. IGM Biosciences Y-mAbs Therapeutics Rocket Pharmaceuticals Cryoport Amarin Cybin TG Therapeutics Prestige Consumer Healthcare Merus Perrigo Aurinia Pharmaceuticals (NASDAQ:AUPH) and IGM Biosciences (NASDAQ:IGMS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, community ranking, risk, profitability, media sentiment and institutional ownership. Does the MarketBeat Community favor AUPH or IGMS? Aurinia Pharmaceuticals received 500 more outperform votes than IGM Biosciences when rated by MarketBeat users. Likewise, 73.17% of users gave Aurinia Pharmaceuticals an outperform vote while only 50.00% of users gave IGM Biosciences an outperform vote. CompanyUnderperformOutperformAurinia PharmaceuticalsOutperform Votes57073.17% Underperform Votes20926.83% IGM BiosciencesOutperform Votes7050.00% Underperform Votes7050.00% Does the media prefer AUPH or IGMS? In the previous week, IGM Biosciences had 1 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 3 mentions for IGM Biosciences and 2 mentions for Aurinia Pharmaceuticals. IGM Biosciences' average media sentiment score of 0.44 beat Aurinia Pharmaceuticals' score of 0.00 indicating that IGM Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral IGM Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, AUPH or IGMS? Aurinia Pharmaceuticals has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500. Comparatively, IGM Biosciences has a beta of 0.2, suggesting that its share price is 80% less volatile than the S&P 500. Do insiders & institutionals have more ownership in AUPH or IGMS? 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 42.8% of IGM Biosciences shares are owned by institutional investors. 4.3% of Aurinia Pharmaceuticals shares are owned by insiders. Comparatively, 57.0% of IGM Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has higher valuation and earnings, AUPH or IGMS? Aurinia Pharmaceuticals has higher revenue and earnings than IGM Biosciences. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than IGM Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAurinia Pharmaceuticals$175.51M5.96-$78.02M-$0.34-21.53IGM Biosciences$2.91M330.52-$246.42M-$3.67-4.42 Do analysts recommend AUPH or IGMS? Aurinia Pharmaceuticals presently has a consensus price target of $10.00, suggesting a potential upside of 36.61%. IGM Biosciences has a consensus price target of $15.00, suggesting a potential downside of 7.52%. Given Aurinia Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Aurinia Pharmaceuticals is more favorable than IGM Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurinia Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75IGM Biosciences 1 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.33 Is AUPH or IGMS more profitable? Aurinia Pharmaceuticals has a net margin of -24.31% compared to IGM Biosciences' net margin of -7,571.35%. Aurinia Pharmaceuticals' return on equity of -11.84% beat IGM Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Aurinia Pharmaceuticals-24.31% -11.84% -8.25% IGM Biosciences -7,571.35%-119.02%-54.74% SummaryAurinia Pharmaceuticals beats IGM Biosciences on 11 of the 18 factors compared between the two stocks. Ad Porter & CompanyWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. Get Aurinia Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AUPH vs. The Competition Export to ExcelMetricAurinia PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.05B$7.03B$5.40B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-21.539.93115.5615.18Price / Sales5.96381.421,484.3492.77Price / CashN/A47.3439.6634.07Price / Book2.785.324.665.02Net Income-$78.02M$153.56M$119.06M$225.46M7 Day Performance3.83%0.11%0.80%0.37%1 Month Performance2.81%15.22%5.65%3.57%1 Year Performance-7.11%41.14%36.76%29.44% Aurinia Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AUPHAurinia Pharmaceuticals2.3482 of 5 stars$7.32+1.5%$10.00+36.6%+2.7%$1.05B$175.51M-21.53300Upcoming EarningsNews CoverageIGMSIGM Biosciences3.7141 of 5 stars$17.60+2.0%$15.00-14.8%+286.2%$1.04B$2.91M-4.80190Short Interest ↓Gap UpYMABY-mAbs Therapeutics3.3056 of 5 stars$14.85+0.7%$21.14+42.4%+163.2%$661.86M$86.55M-26.52150Upcoming EarningsNews CoveragePositive NewsRCKTRocket Pharmaceuticals4.3151 of 5 stars$16.97-2.2%$51.75+204.9%-10.6%$1.54BN/A-6.08240Upcoming EarningsCYRXCryoport2.515 of 5 stars$6.81-5.4%$12.00+76.2%-24.9%$335.44M$225.61M-1.861,170Upcoming EarningsShort Interest ↑News CoverageAMRNAmarin0.3866 of 5 stars$0.60-1.6%N/A-16.0%$247.31M$264.78M-7.53360News CoverageCYBNCybin1.8174 of 5 stars$9.91-5.6%$50.50+409.6%N/A$4.07BN/A-1.6350TGTXTG Therapeutics4.7929 of 5 stars$25.13-2.3%$34.43+37.0%+165.8%$3.88B$346.72M41.20290Upcoming EarningsAnalyst ForecastNews CoveragePBHPrestige Consumer Healthcare4.3625 of 5 stars$73.56+0.0%$94.20+28.1%+24.4%$3.65B$1.13B17.99540Upcoming EarningsNews CoveragePositive NewsMRUSMerus1.6823 of 5 stars$51.28-1.2%$81.09+58.1%+141.9%$3.50B$43.95M-17.5637Analyst ForecastNews CoveragePRGOPerrigo4.9081 of 5 stars$25.43-3.6%$37.00+45.5%-6.9%$3.47B$4.43B-27.649,140Upcoming EarningsDividend Announcement Related Companies and Tools Related Companies IGMS Alternatives YMAB Alternatives RCKT Alternatives CYRX Alternatives AMRN Alternatives CYBN Alternatives TGTX Alternatives PBH Alternatives MRUS Alternatives PRGO Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AUPH) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aurinia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aurinia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
